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Abstract
Ischaemic heart disease and cerebrovascular disease are among the leading causes of death
in Australian men and women with heart diseases being the third highest cause of death in
Australian women and fourth highest cause of death in Australian men (AIHW, 2006). In
Australia more than 50% of all adults have two or three (out of a possible nine) risk factors
for cardiovascular disease and 15% having four or more risk factors.
It has long been recognised that diet modification can reduce these risks. Recently dietary
advice has moved from an “exclusionary” to an “inclusionary” paradigm. That is, rather
than identify dietary items to avoid, current guidelines recommend incorporating advice to
increase the consumption of a range of functional foods including marine sourced omega-3
fatty acids EPA and DHA and vegetable oils.
EPA and DHA are effective functional foods in reducing CVD mortality, cardiac death,
sudden death and myocardial infarction. EPA and DHA provide this cardiovascular benefit
by improving several risk factors including: fasting plasma triglycerides, blood pressure
and arterial compliance. However, a safety concern of dietary EPA and DHA
supplementation is their capacity to cause a significant increase in LDL cholesterol
concentrations.
Dietary intake levels of EPA and DHA in the Australian diet are well below those
associated with reductions in CVD risk. In 50% of the population a potential 20 – fold
increase in EPA and DHA would be required to increase intake levels to those
commensurate with reduced CVD risk.
While dietary supplementation with EPA and DHA is one means of increasing dietary
intake levels, strategies to increase the efficacy of EPA and DHA would also be
advantageous and could reduce supplement doses. Dietary strategies that could
simultaneously counteract the rise in LDL cholesterol caused by DHA would also be
beneficial.

xii

The research described in this thesis aimed to modify the bioavailability and cardiovascular
effects of DHA by modifying other dietary factors and combining DHA with other active
ingredients. To address these aims two human clinical trials were conducted. The first
examined the effect of altering the types of oil and margarine consumed in the diet with
view to reducing the dietary intake of omega-6 fatty acids while supplementing the diet
with DHA-rich fish oil (MOFO study). This study showed that replacing usual dietary oil
and margarine with canola products while supplementing the diet with 1.1g/d of DHA
favourably improved total omega-3 fatty acid incorporation and reduced the omega-6:
omega-3 fatty acid ratio in plasma and erythrocyte membrane phospholipids as effectively
as double the supplement dose of DHA. Additionally, there was a similar rise in erythrocyte
membrane and plasma DHA when either safflower or sunola oil, which contain very
different amounts of linoleic acid, were consumed concurrently with a daily dietary
supplementation of 1.1g/d of DHA. A distinguishing feature of canola is its relatively high
omega-3 ALA content. Thus, these findings add to the body of scientific evidence
supporting the view that the total amount of dietary omega-3 consumed has greater impact
on the bioavailability of supplemented DHA than the ratio of dietary omega-6: omega-3
fatty acids.
The MOFO study also showed that the combination of canola plus 1.1g/d of DHA is
equally as effective as daily supplementation with 2.2g/d of DHA at reducing fasting
plasma triglyceride concentrations with the added benefit of preventing the significant rise
in both LDL and total cholesterol caused by both doses of DHA alone. While further
research is warranted based on the findings from animal studies, it can reasonably be
proposed that the findings from the MOFO study may be an example of a synergistic effect
of canola phytosterols and DHA, rather than ALA and DHA, working together to
significantly reduce fasting plasma triglyceride concentrations while preventing detrimental
effects on LDL cholesterol in people with mild hypertriglyceridemia.
The second human clinical trial conducted as part of this thesis examined the effect of
combining omega-3 fatty acids with soy isoflavones on fasting blood lipids, blood pressure
and arterial compliance (Omega-Soy study). The Omega-Soy study showed that the
xiii

combined consumption of DHA with soy isoflavones resulted in an 8-10% improvement in
HDL cholesterol, an 18-20% reduction in plasma triglyceride concentrations and the
absence of a 10.8% rise in LDL cholesterol observed with DHA supplementation alone.
Furthermore, the increases in LDL and total cholesterol observed with DHA
supplementation in the first six weeks were reversed and significantly reduced when soy
cereal was concurrently consumed. The results showed that the dietary combination of soy
isoflavones and DHA improve the lipid profile of moderately hyperlipidemic individuals
more favourably than either constituent alone.
While further research is warranted based on evidence from in vitro cell culture and in vivo
animal models demonstrating functional effects of soy isoflavones and DHA on lipid
metabolism pathways, it can reasonably be proposed that the findings from the Omega-Soy
study demonstrate a synergistic effect of soy isoflavones and DHA, working together to
significantly reduce fasting plasma triglyceride concentrations without detrimental effects
on LDL cholesterol in people with mild hyperlipidemia.
The findings from this thesis support two functional food synergies for effective
improvement of blood lipid concentrations when consumed as part of the usual diet of men
and postmenopausal women with moderately elevated blood lipids. These functional food
combinations are DHA with canola and DHA with soy isoflavones. The findings of this
thesis sheds some light on how isoflavones may be actively involved in reducing plasma
cholesterol concentrations when consumed with soy protein or in soy containing foods,
furthermore the findings of this thesis provide strategies for ultimately reducing the
negative side effects of dietary DHA supplementation and for achieving a better outcome in
overall lipid profile improvements than could be achieved with DHA supplementation
alone. Future research into these synergistic combinations of functional food ingredients
with DHA may lead to new directions in functional food development by food
manufacturers to enable more consumers to manage their blood lipid concentrations with
minimal or without drug therapy requirements.
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